ArticlePloS one2009
The intracellular localization of ID2 expression has a predictive value in non small cell lung cancer.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Varied pathways of stage IA lung adenocarcinomas discovered by integrated gene expression analysis.International journal of biological sciences · 2011Pooled it
- Effects of methylation and transcription factor YY1 on ID2 expression in non-small cell lung carcinoma cells.American journal of cancer research · 2024Article
- SMURF2 facilitates ubiquitin-mediated degradation of ID2 to attenuate lung cancer cell proliferation.International journal of biological sciences · 2023Article
- Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis.Biology · 2022Article
- Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.Oncogene · 2022Article
- Id2 exerts tumor suppressor properties in lung cancer through its effects on cancer cell invasion and migration.Frontiers in oncology · 2022Article
- High-Throughput Screen of Natural Compounds and Biomarkers for NSCLC Treatment by Differential Expression and Weighted Gene Coexpression Network Analysis (WGCNA).BioMed research international · 2021Article
- ID2 Inhibits Bladder Cancer Progression and MetastasisFrontiers in cell and developmental biology · 2021Article
- Comprehensive analysis of inhibitor of differentiation/DNA-binding gene family in lung cancer using bioinformatics methods.Bioscience reports · 2020Article
- Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.Genome biology · 2019Article
- Inhibitor of DNA Binding 2 Inhibits Epithelial-Mesenchymal Transition via Up-Regulation of Notch3 in Breast Cancer.Translational oncology · 2018Article
- Prognostic values of the inhibitor of DNA‑binding family members in breast cancer.Oncology reports · 2018Article
- E Proteins and ID Proteins: Helix-Loop-Helix Partners in Development and Disease.Developmental cell · 2015Review
- Snail interacts with Id2 in the regulation of TNF-α-induced cancer cell invasion and migration in OSCC.American journal of cancer research · 2015Article
- Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.Nature genetics · 2014Article
- Article
- Id2 complexes with the SNAG domain of Snai1 inhibiting Snai1-mediated repression of integrin β4.Molecular and cellular biology · 2013Article
- Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines.PloS one · 2013Article
- Differential transcriptomic analysis of spontaneous lung tumors in B6C3F1 mice: comparison to human non-small cell lung cancer.Toxicologic pathology · 2012Article
- Genome-scale study of transcription factor expression in the branching mouse lung.Developmental dynamics : an official publication of the American Association of Anatomists · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundID2 is a member of a subclass of transcription regulators belonging to the general bHLH (basic-helix-loop-helix) family of transcription factors. In normal cells, ID2 is responsible for regulating the balance between proliferation and differentiation. More recent studies have demonstrated that ID2 is involved in tumor progression in several cancer types such as prostate or breast. METHODOLOGY/PRINCIPAL
findingsIn this work, we investigated, for the first time, the relationship between the expression of ID2 in non-small cell lung cancer (NSCLC) patients and the clinicopathological features and prognosis of these patients. Immunohistochemistry was performed on tissue microarrays, which included 62 NSCLC tumors. In malignant tissues, ID2 expression has been detected in both the nuclear and cytoplasmic compartments, but we have demonstrated that only nuclear expression of ID2 is inversely correlated with the differentiation grade of the tumor (p = 0.007). Interestingly, among patients with poorly differentiated tumors, high nuclear expression of ID2 was an independent and unfavorable prognostic factor for survival (p = 0.036).
conclusionsThese results suggest that ID2 could be involved in tumor dedifferentiation processes of NSCLC, and could be used as prognostic marker for patients with poorly differentiated tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.